Theravance Biopharma announced a definitive agreement for acquisition by Zymeworks, expected to close in the second half of 2026 pending shareholder approval. The company's Q2 2026 revenue rose 11% year-over-year to $20.7 million, driven by growth in YUPELRI sales and improved operating leverage. Significant cost reductions were achieved through restructuring, cutting operating expenses by 35% year-over-year. Theravance maintains a strong cash position of $388 million with no debt and expects further cost savings and milestone payments tied to TRELEGY sales in 2026.
President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of...
Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...
President Donald Trump signed an executive order to separate the combined MMR vaccine into three individual shots, citing unproven claims linking the combined vaccine to autism. Medical experts strongly reject this, emphasizing the vaccine's safety a...
